June 2019 - Volume 3 - Issue S1 - Contributor Index

Author:
Gašic, V.
Author:
Gabarros, M.
Author:
Gabbasova, S.
Author:
Gabcova, G.
Author:
Gabdoulline, R.
Author:
Gabeeva, N.

PB2016 RESULTS OF TREATMENT PATIENTS OF MANTLE CELL LYMPHOMA DEPENDING ON THE MUTATIONAL STATUS OF THE TP53 GENE

Koroleva, D.; Zvonkov, E.; Gabeeva, N.; More

HemaSphere. 3(S1):912, June 2019.

Author:
Gabellini, D.
Author:
gaber, M.
Author:
Gabillaud, C.

PB1868 B-CELL PROLYMPHOCYTIC LEUKEMIA (B-PLL) AND PROLYMPHOCYTOID MANTLE CELL LYMPHOMA (PMCL) (MORE THAN 55% OF PROLYMPHOCYTES) ARE CLOSED BUT DISTINCT ENTITIES. ON BEHALF GFCH AND FILO GROUPS

Chapiro, E.; Diop, K.; Dessen, P.; More

HemaSphere. 3(S1):851-852, June 2019.

Author:
Gablo, N.
Author:
Gabriel, J.
Author:
Gabriel, L.R.

PS1402 OUTCOME IN TRANSPLANT ELIGIBLE PATIENTS WITH MULTIPLE MYELOMA IN LATIN AMERICA. AN INTERNATIONAL STUDY OF GELAMM

Peña, C.; Schutz, N.P.; Bove, V.; More

HemaSphere. 3(S1):643-644, June 2019.

Author:
Gabrion, A.

PF441 RED BLOOD CELLS PROPERTIES IN PATIENTS WITH SICKLE CELL DISEASE TREATED WITH LENTIGLOBIN GENE THERAPY IN THE HGB-205 TRIAL

Magrin, E.; Semeraro, M.; Hebert, N.; More

HemaSphere. 3(S1):173-174, June 2019.

Author:
Gachard, N.
Author:
Gade, A.
Author:
Gadisseur, A.
Author:
Gafarova, S.
Author:
Gaffo, E.

PF325 REAL - LIFE DATA ON ROMIDEPSIN TREATMENT FOR RELAPSED AND REFRACTORY PERIPHERAL AND CUTANEOUS T-CELL LYMPHOMA - A MULTICENTER NATIONAL OBSERVATIONAL STUDY

Shimony, S.; Horowitz, N.; Ribakovsky, E.; More

HemaSphere. 3(S1):115, June 2019.

Author:
Gagliardi, A.
Author:
Gaidano, G.

S104 THE BRAF INHIBITOR VEMURAFENIB COMBINED WITH RITUXIMAB PRODUCES A HIGH RATE OF DEEP AND DURABLE REMISSIONS IN RELAPSED OR REFRACTORY HAIRY CELL LEUKEMIA: UPDATED RESULTS OF A PHASE-2 TRIAL

Tiacci, E.; De Carolis, L.; Simonetti, E.; More

HemaSphere. 3(S1):3, June 2019.

PF296 UPDATE OF THE SINGLE-ARM PHASE II L-MIND STUDY OF MOR208 PLUS LENALIDOMIDE IN RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA: HIGH OVERALL RESPONSE RATES IN PATIENT SUBGROUPS WITH POOR PROGNOSIS

Duell, J.; Maddocks, K.; González Barca, E.; More

HemaSphere. 3(S1):100, June 2019.

PF365 PROGNOSTIC IMPLICATIONS OF IGHV GENE REARRANGEMENTS WITH “BORDERLINE” PERCENTAGE OF MUTATIONS IN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS

Raponi, S.; Ilari, C.; Della Starza, I.; More

HemaSphere. 3(S1):134-135, June 2019.

PF375 IBRUTINIB AND RITUXIMAB AS FRONT-LINE TREATMENT FOR UNFIT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL). PRELIMINARY RESULTS FROM THE GIMEMA LLC1114 STUDY

Mauro, F.R.; Molica, S.; Paoloni, F.; More

HemaSphere. 3(S1):139, June 2019.

PF586 SPARING STEROIDS IN ELDERLY INTERMEDIATE-FIT NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS TREATED WITH A DOSE/SCHEDULE-ADJUSTED RD-R VS. CONTINUOUS RD: RESULTS OF RV-MM-PI-0752 PHASE III RANDOMIZED STUDY

Larocca, A.; Salvini, M.; Gaidano, G.; More

HemaSphere. 3(S1):244, June 2019.

PS1248 COMPREHENSIVE ANALYSIS OF BASELINE OUTCOME BIOPREDICTORS IN YOUNGER PATIENTS WITH MANTLE CELL LYMPHOMA: THE ANCILLARY BIOLOGICAL STUDIES OF FONDAZIONE ITALIANA LINFOMI (FIL) MCL0208 CLINICAL TRIAL

Ferrero, S.; Zaccaria, G.M.; Barbero, D.; More

HemaSphere. 3(S1):569-570, June 2019.

Author:
Gaidzik, V.I.

S1616 MEASURABLE RESIDUAL DISEASE MONITORING IN ACUTE MYELOID LEUKEMIA (AML) WITH T(8;21)(Q22;Q22.1); RUNX1-RUNX1T1: RESULTS OF THE AML STUDY GROUP (AMLSG)

Rücker, F.G.; Agrawal, M.; Corbacioglu, A.; More

HemaSphere. 3(S1):745-746, June 2019.

Author:
Gaillard, B.

PB1868 B-CELL PROLYMPHOCYTIC LEUKEMIA (B-PLL) AND PROLYMPHOCYTOID MANTLE CELL LYMPHOMA (PMCL) (MORE THAN 55% OF PROLYMPHOCYTES) ARE CLOSED BUT DISTINCT ENTITIES. ON BEHALF GFCH AND FILO GROUPS

Chapiro, E.; Diop, K.; Dessen, P.; More

HemaSphere. 3(S1):851-852, June 2019.

Author:
Gainaru, G.

PF297 COMPARISON OF RITUXIMAB DOSE-ADJUSTED EPOCH (R-DA-EPOCH) WITH RITUXIMAB-CHOP (R-CHOP) CHEMOTHERAPY IN PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA (PMLBCL)

Vassilakopoulos, T.; Mellios, Z.; Verigou, E.; More

HemaSphere. 3(S1):100-101, June 2019.

PS1089 PET-SCAN FOR RESPONSE ASSESSEMENT AFTER RITUXIMAB-DOSE-ADJUSTED-EPOCH (R-DA-EPOCH) IN PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA (PMLBCL): CLINICAL AND PROGNOSTIC SIGNIFICANCE

Vassilakopoulos, T.; Chatzidimitriou, C.; Mellios, Z.; More

HemaSphere. 3(S1):494, June 2019.

Author:
Gaipa, G.

PF436 GMP MANUFACTURING OF ALLOGENEIC CD19 CHIMERIC ANTIGEN RECEPTOR (CAR) CYTOKINE INDUCED KILLER (CIK) CELLS WITH SLEEPING BEAUTY (SB) TRANSPOSON FOR ADOPTIVE IMMUNOTHERAPY

Magnani, C.F.; Gaipa, G.; Belotti, D.; More

HemaSphere. 3(S1):171, June 2019.

Author:
Gajdos, P.
Author:
Gakiopoulou, C.

PS1378 AN EARLY, WITHIN THE FIRST MONTH, AND DEEP RESPONSE, SHOULD BE THE GOAL OF THERAPY IN AL AMYLOIDOSIS

Kastritis, E.; Karatrasoglou, E.A.; Dialoupi, I.; More

HemaSphere. 3(S1):630-631, June 2019.

PS1392 CONSOLIDATION WITH A SHORT COURSE OF DARATUMUMAB CAN SIGNIFICANTLY IMPROVE COMPLETE RESPONSE RATES IN PATIENTS WITH AL AMYLOIDOSIS OR LCDD

Kastritis, E.; Gavriatopoulou, M.; Kostopoulos, I.V.; More

HemaSphere. 3(S1):638-639, June 2019.

PS1393 PRIMARY TREATMENT OF LIGHT CHAIN (AL) AMYLOIDOSIS WITH BORTEZOMIB, LENALIDOMIDE AND DEXAMETHASONE (VRD)

Kastritis, E.; Dialoupi, I.; Gavriatopoulou, M.; More

HemaSphere. 3(S1):639, June 2019.

Author:
Gal’tseva, I.
Author:
Galacteros, F.
Author:
galal, S.

PF537 THE STAT SIGNALING BIOSIGNATURE OF CD4+ T CELL SUBSETS REFLECT THE IMMUNOGENICITY OF HIGH-RISK MDS AND PREDICT AZACYTIDINE TREATMENT OUTCOME

Lamprianidou, E.; Kordella, C.; Zoulia, E.; More

HemaSphere. 3(S1):221-222, June 2019.

PF693 PRIMARY IMMUNE THROMBOCYTOPENIA (ITP) IN THE ELRDELRY AND YOUNGER ADULTS: REAL-WORLD COMPARATIVE RETROSPECTIVE STUDY FROM THE ITP REGISTRY OF THE HELLENIC SOCIETY OF HEMATOLOGY

Pontikoglou, C.; Kaliafentaki, V.; Stavroulaki, E.; More

HemaSphere. 3(S1):301, June 2019.

S840 IMPACT OF 1ST LINE TREATMENT ON OVERALL SURVIVAL IN 1.633 PATIENTS WITH CHRONIC MYELOMONOCYTIC LEUKEMIA – A MULTINATIONAL COLLABORATIVE EFFORT COORDINATED BY THE AGMT STUDY GROUP

Pleyer, L.; Leisch, M.; Kouraklis, A.; More

HemaSphere. 3(S1):374-375, June 2019.

PF563 MARROW INFILTRATING T-REGULATORY CELLS ASSOCIATE WITH PD-1 EXPRESSING CD4 EFFECTOR CELLS AND INFERIOR OUTCOMES IN PATIENTS UNDERGOING NOVEL-AGENT REGIMENS FOR NEWLY DIAGNOSED MULTIPLE MYELOMA (MM)

Alrasheed, N.; Lee, L.; Ghorani, E.; More

HemaSphere. 3(S1):233-234, June 2019.

Author:
Galassi, L.

PS1274 EPIDEMIOLOGY AND MANAGEMENT OF LATENT TUBERCULOSIS INFECTION IN ADULT PATIENTS WITH ACUTE LEUKEMIA OR APLASTIC ANEMIA: A RETROSPECTIVE MONOCENTER STUDY

Bettelli, F.; Giusti, D.; Morselli, M.; More

HemaSphere. 3(S1):583, June 2019.

Author:
Galaverna, F.

S1624 A DAY 100 LAB-SCORE PREDICTS EXTENSIVE CGVHD, OVERALL SURVIVAL AND TRANSPLANT-RELATED MORTALITY AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION: FINAL ANALYSIS

Metafuni, E.; Cavattoni, I.; Lamparellli, T.; More

HemaSphere. 3(S1):750, June 2019.

Author:
Galayko, M.

PF422 THE LONG-TERM TREATMENT RESULTS OF THE MULTICENTER EUTOS ELN POPULATION-BASED STUDY (EUTOS-PBS) IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA IN RUSSIAN FEDERATION

Lazareva, O.; Turkina, A.; Chelysheva, E.; More

HemaSphere. 3(S1):164-165, June 2019.

Author:
Gale, R.

PF218 DDX11 MUTATIONS AND CLONAL TRAJECTORY PATTERNS IN ADULTS WITH CYTOGENETICALLY-NORMAL ACUTE MYELOID LEUKEMIA

Zhou, Y.-L.; Wu, L.-X.; Wang, Z.-L.; More

HemaSphere. 3(S1):61, June 2019.

Author:
Galende, J.

S896 SYNTHETIC LETHAL EFFECTS OF DUAL BCR AND PARP INHIBITION IN PROLIFERATIVE DEL(11Q) CLL CELLS IN THE PRESENCE OF STROMAL STIMULATION

Quijada-Álamo, M.; Hernández-Sánchez, M.; Rodríguez-Vicente, A.E.; More

HemaSphere. 3(S1):403-404, June 2019.

Author:
Galieni, P.

PF579 TUMOR CIRCULATING PLASMA CELLS DETECTED BY FLOW CYTOMETRIC SINGLE PLATFORM METHOD ARE RELATED TO NEGATIVE PATIENTS‘ CHARACTERISTICS IN MULTIPLE MYELOMA

Muccio, V.E.; Gilestro, M.; Saraci, E.; More

HemaSphere. 3(S1):241-242, June 2019.

PF602 OUTCOME OF EXTRA-MEDULLARY DISEASE IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS TREATED WITH NEW DRUGS

Montefusco, V.; Gay, F.; Spada, S.; More

HemaSphere. 3(S1):254-255, June 2019.

Author:
Galimberti, S.

S123 SETD2 LOSS OF FUNCTION IS A RECURRENT EVENT IN ADVANCED-PHASE CHRONIC MYELOID LEUKEMIA INDUCED BY POST-TRANSLATIONAL MECHANISMS THAT CAN BE THERAPEUTICALLY TARGETED

Mancini, M.; De Santis, S.; Monaldi, C.; More

HemaSphere. 3(S1):13-14, June 2019.

PF172 PROSPECTIVE COMPARISON OF SANGER SEQUENCING VS NEXT GENERATION SEQUENCING FOR ROUTINE BCR-ABL1 KINASE DOMAIN MUTATION SCREENING IN PHILADELPHIA-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS

Soverini, S.; Martelli, M.; Bavaro, L.; More

HemaSphere. 3(S1):37-38, June 2019.

PF420 RESULTS OF A PROSPECTIVE MULTICENTER STUDY ON PRO-ATHEROTHROMBOTIC EFFECT INDUCED BY TYROSINE-KINASE INHIBITORS FOR FIRST-LINE TREATMENT OF CML PTS (KIARO TRIAL)

Sicuranza, A.; Zuanelli Brambilla, C.; Ferrigno, I.; More

HemaSphere. 3(S1):163-164, June 2019.

Author:
Galinsky, J.
Author:
Gallamini, A.

S820 FRONTLINE BRENTUXIMAB VEDOTIN WITH CHEMOTHERAPY FOR STAGE 3/4 CLASSICAL HODGKIN LYMPHOMA: 3-YEAR UPDATE OF THE ECHELON-1 STUDY

Gallamini, A.; Straus, D.; Dlugosz-Danecka, M.; More

HemaSphere. 3(S1):362-363, June 2019.

PS1237 DOSE DENSE ABVD (DD-ABVD) AS FIRST LINE THERAPY IN EARLY-STAGE UNFAVOURABLE HODGKIN LYMPHOMA (CHL): RESULTS OF A PHASE II, PROSPECTIVE, MULTI-CENTER STUDY BY FONDAZIONE ITALIANA LINFOMI

Mazza, R.; Spina, M.; Califano, C.; More

HemaSphere. 3(S1):563-564, June 2019.

Author:
Gallardo, M.
Author:
Gallay, N.

PF200 CARBENOXOLONE REVERSES MICROENVIRONMENT-INDUCED CHEMORESISTANCE OF ACUTE MYELOID LEUKEMIA

Kouzi, F.; Zibara, K.; Picou, F.; More

HemaSphere. 3(S1):52-53, June 2019.

PS989 ABNORMAL DNA METHYLATION MODIFIES HOX GENES EXPRESSION IN BONE MARROW MESENCHYMAL STROMAL CELLS OF MYELODYSPLASIAS AND DE NOVO ACUTE MYELOID LEUKEMIAS

Roux, B.; Picou, F.; Vignon, C.; More

HemaSphere. 3(S1):444, June 2019.

Author:
Gallego, P.
Author:
Galler, C.

S105 GENETIC MARKERS AND OUTCOME IN THE CLL14 TRIAL OF THE GCLLSG COMPARING FRONT LINE OBINUTUZUMAB PLUS CHLORAMBUCIL OR VENETOCLAX IN PATIENTS WITH COMORBIDITY

Tausch, E.; Bahlo, J.; Robrecht, S.; More

HemaSphere. 3(S1):4, June 2019.

Author:
Galli, A.
Author:
Galli, E.

PF759 ALLOGENEIC STEM CELL TRANSPLANTATION FOR HEMATOLOGICAL MALIGNANCIES FROM HLA IDENTICAL SIBLINGS OR HAPLOIDENTICAL DONORS: A COMPARISON

Corbingi, A.; Dragonetti, G.; Galli, E.; More

HemaSphere. 3(S1):333-334, June 2019.

Author:
Galli, M.

S872 CARFILZOMIB LENALIDOMIDE DEXAMETHASONE (KRD) WITH OR WITHOUT TRANSPLANTATION IN NEWLY DIAGNOSED MYELOMA (FORTE TRIAL): EFFICACY ACCORDING TO RISK STATUS

Gay, F.; Cerrato, C.; Rota Scalabrini, D.; More

HemaSphere. 3(S1):390-391, June 2019.

Author:
Gallur, L.